Phase 3 Pancreatic Cancer Trial, Recruiting NCT07252232 Sponsor: Revolution Medicines, Inc. Condition: Pancreatic Cancer
Back to Pancreatic Cancer

Phase 3 Pancreatic Cancer Trial, Recruiting

NCT07252232
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are at least 18 years old and have agreed to take part by signing a consent form
  • People whose general health and ability to carry out daily activities meets a certain level, known as an ECOG score of 0 or 1 — meaning fully active or restricted in strenuous activity only (confirm with trial site)
  • People who have been diagnosed with pancreatic ductal adenocarcinoma (a specific type of pancreatic cancer) confirmed by laboratory testing of tissue, and who have had surgery aimed at removing all or most of the cancer
  • People who show no signs of the cancer returning or spreading after surgery
  • People who have received chemotherapy involving more than one drug, either before surgery, after surgery, or both
  • People who finished their most recent cancer treatment within the past 12 weeks
  • People whose bone marrow, liver, kidneys, and blood clotting are all functioning at an adequate level (confirm with trial site)
  • People who have had testing done to determine whether a specific gene change called a RAS mutation is present in their cancer
  • People who are able to swallow and take oral (by mouth) medications

Who may not be able to join:

  • People who have previously received any treatment that directly targets the RAS protein, such as RAS inhibitors or degraders
  • People who have any condition that could interfere with taking or absorbing the study drug by mouth
  • People who have had a major surgical procedure within 28 days before being enrolled in the trial
  • People who are unable or unwilling to attend required visits or complete required procedures as set out in the trial plan

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 1-844-2-REVMED

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Revolution Medicines, Inc.
Registry
ClinicalTrials.gov
Start date
15 December 2025
Est. completion
10 May 2029

Where this trial is recruiting

🇫🇷 France 🇮🇹 Italy 🇯🇵 Japan Puerto Rico 🇪🇸 Spain 🇬🇧 United Kingdom 🇺🇸 United States

Primary endpoints

Disease-Free Survival (DFS) per Investigator

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov